우리나라 건강보험 청구자료를 이용한 알츠하이머성 치매 치료제의 사용현황 분석
Study of the Drugs Prescribed on Alzheimer's Disease: from the Insurance Claims Data of Korea National Health Insurance Service
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Objective: The aims of this study are to investigate the total volume of prescribed medicines against Alzheimer’s disease(AD) and the trends of usage by analyzing the claims-data from the Korea National Health Insurance Service. Method: The demographic and claims-data were included the major AD treating medicines such as donepezil, galantamine,rivastigmine and memantine, and analyzed during the period of 2010~2012. The assessing criteria were gender,age, habitation, types of medical institution, code of ingredients, outcomes of treatment, volume and amount of claims,and the numbers of patients with dementias. After trimming the data, it were analyzed by the market size, demographictraits, characteristics of medical service, characteristics of each anti-AD medicine, etc. Results: Among the chosen4 medicines, donepezil had the top prescription volumes. Most prevalent prescribing preparations of donepezil wereconventional types. However, among the non-conventional types, oro-dispersible formulation is the fast increasing onein both volume and growth rate. This specialized preparations to improve both toleration and adherence, tend to beingprescribed generally at the tertiary medical institutions. While the younger patients with mild-to-moderate AD mostlytreated by expensive medicines in resident at the tertiary hospitals, the rest older patients with severe AD have beentreated non-expensive one at long-term care facilities. Conclusion: AD is a chronic illness therefore, long-term use oftherapeutic medications are highly important. If an anti-AD treatment was applied steadily in the earlier stages, it wouldbe achieved not only improving the quality of life of patient but also reducing the expenses in the medical and nursingcares. As the socioeconomical impacts of AD is expanding, healthcare professionals need to aware the importance ofpharmacotherapy and to improve sociopolitical fundamentals.
Abstract
Objective: The aims of this study are to investigate the total volume of prescribed medicines against Alzheimer’s disease(AD) and the trends of usage by analyzing the claims-data from the Korea National Health Insurance Service. Method: The demographic and claims-data were included the major AD treating medicines such as donepezil, galantamine,rivastigmine and memantine, and analyzed during the period of 2010~2012. The assessing criteria were gender,age, habitation, types of medical institution, code of ingredients, outcomes of treatment, volume and amount of claims,and the numbers of patients with dementias. After trimming the data, it were analyzed by the market size, demographictraits, characteristics of medical service, characteristics of each anti-AD medicine, etc. Results: Among the chosen4 medicines, donepezil had the top prescription volumes. Most prevalent prescribing preparations of donepezil wereconventional types. However, among the non-conventional types, oro-dispersible formulation is the fast increasing onein both volume and growth rate. This specialized preparations to improve both toleration and adherence, tend to beingprescribed generally at the tertiary medical institutions. While the younger patients with mild-to-moderate AD mostlytreated by expensive medicines in resident at the tertiary hospitals, the rest older patients with severe AD have beentreated non-expensive one at long-term care facilities. Conclusion: AD is a chronic illness therefore, long-term use oftherapeutic medications are highly important. If an anti-AD treatment was applied steadily in the earlier stages, it wouldbe achieved not only improving the quality of life of patient but also reducing the expenses in the medical and nursingcares. As the socioeconomical impacts of AD is expanding, healthcare professionals need to aware the importance ofpharmacotherapy and to improve sociopolitical fundamentals.
참고문헌 (25)
- Annual Reports of Center for Treatment of Dementias in Korea, , ~ (2013)
- National Plan of Management for Dementia, , Korea Ministry of Food and Drug Safety, ~ (2012)
- Katzman R., "Education and the prevalence of dementia and Alzheimer's disease among community dwelling elderly persons and their first relatives", Ann Neurol, 33, pp.494~501 (1993)
- Clinical Therapeutic Guideline for Dementias, , Korea Ministry of Food and Drug Safety, ~ (2009)
- Statistical Data of Health Insurance in Korea (2010~2013), , Health Insurance Review & Assessment Service in Korea, ~
- 이강수, "알츠하이머 치매 치료제: 현위치와 향후 전망", 대한정신약물학회지, 23(4), pp.131~135 (2012), 대한정신약물학회
- 이동우, "알츠하이머병에 대한 근거중심 처방", 대한의사협회지, 52(4), pp.417~425 (2009), 대한의사협회
- NICE technology appraisal guidance 217, "rivastigmine and memantine for the treatment of Alzheimer’s disease (review of NICE technology appraisal guidance 111)", ~ (2011)
- Geldmacher DS., "Treatment Guidelines for Alzheimer's Disease : Redefining Perceptions in Primary Care", Prim Care Companion J Clin Psychiatry, 9(2), pp.113~121 (2007)
- Farlow MR, "Effective Pharmacologic Management of Alzheimer's Disease", Am J Med, 120, pp.388~397 (2007)
- "Cholinesterase inhibitors for Alzheimer's disease", Cochrane Database of Systematic Reviews, (1), pp.CD005593~ (1858)[DOI]
- Winblad B., "IDEAL: a 6- month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease", Neurology, 69(Suppl 1), pp.S14S22~ (2007)
- 허재혁, "건강보험심사평가원 자료를 이용한 5년간(2003-2007년) 치매 환자치료 추세동향", Dementia and Neurocognitive Disorders(대한치매학회지), 9(1), pp.29~35 (2010), 대한치매학회
- Kim JM., "Current problems and resolutions on the health policies for patients with dementias", Public Administration and Research, 7(2), pp.133~150 (2006)
- "Cholinesterase inhibitors for Alzheimer's disease", Cochrane Database of Systematic Reviews, (1) (2006)
- Background Paper 6.11 Alzheimer Disease and other Dementias, "Tanna S", ~ (2013)
- "Alzheimer's Association of USA"[URL]
- National Plan of Management for Dementia, , Korea Ministry of Food and Drug Safety, ~ (2009)
- Survey of the Prevalence of Dementia in Korea, , Ministry of Health and Welfare, ~ (2008)
- Research and Markets: Global Alzheimer Prevalence and Drugs Demand, "BUSINESS WIRE", ~ (2011)
- "Notice #2013-127 of Korea Ministry of Health and Welfare September 1", ~ (2013)
- Castro DM., "The economic cost of Alzheimer's disease family or public-health burden", Dement Neuropsychol, 4(4), pp.262~267 (2010)
- "Overcome of the barriers in Dementias", News clipping of Medical Observer. Feb. 2014, ~ (2014)